Can Passkey Therapeutics turn drug combinations into a faster clinical strategy?
AI drug platforms need clinical proof. Passkey’s new CMO must show whether Locksmith-picked combinations can move faster into patients.
NeuroSense expands Alzheimer’s IP with U.S. patent, but all eyes are on RoAD trial results
NeuroSense gains a U.S. patent for PrimeC in Alzheimer’s disease. Find out what it means ahead of key trial results due in early 2026.
What OrsoBio’s Phase 1b/2a TLC-6740 results reveal about the limits of GLP-1 monotherapy
OrsoBio’s TLC-6740 combo data hints at a new way to break GLP-1 plateaus. Read what this could change in obesity drug development.
Can next-gen immunotherapy combos finally crack the code in metastatic breast cancer?
The landscape of metastatic breast cancer treatment is facing a fundamental rethink, with the oncology field laser-focused on one of its greatest clinical challenges: how to break immune resistance and stop metastatic spread. Despite a wave of checkpoint inhibitor approvals and initial enthusiasm, progress in metastatic breast cancer—especially for subtypes like triple-negative and HER2-positive disease—has […]